TITLE

Airway-Clearance Therapy Guidelines and Implementation

AUTHOR(S)
Lester, Mary K.; Flume, Patrick A.
PUB. DATE
June 2009
SOURCE
Respiratory Care;Jun2009, Vol. 54 Issue 6, p733
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The clearance of secretions from the lungs of patients with cystic fibrosis (CF) is an important component in the fight to preserve their lung function. There is excessive inflammation in the airways of these patients, which is thought to be exaggerated by ineffective mucociliary clearance and bacterial infection. In 2005 the Cystic Fibrosis Foundation formed the Pulmonary Therapies Committee to review all of the medical literature on the various airway-clearance therapies used in treating CF lung disease. The recommendations were: an airway-clearance therapy should be performed by all patients with CF, no form of airway-clearance therapy stood out as being superior to another, and that patients may express a preference of one therapy over another. They also concluded that aerobic exercise is beneficial to patients with CF, as it is to everyone, and that exercise should be a component to the overall health routine of patients with CF. The challenge for respiratory and physical therapists together with the patient/family is to develop a plan of attack through the use of various airway-clearance therapies. The respiratory and physical therapists are integral in helping patients and families develop airwayclearance routines that aid in the removal of the secretions that cause airway obstruction. There is a wide range of airway-clearance therapies that therapists can choose from when they are teaching the patients and family members the strategies of secretion removal. The questions are: What therapy is best for what age or stage of lung disease? What therapies will the patient do? And which therapies will be covered by medical insurance? These are all fundamental questions that must be answered when guiding families in finding therapies that are effective and appropriate for each CF patient's unique situation.
ACCESSION #
41426962

 

Related Articles

  • EQUAZIONI DI RIFERIMENTO DEL "6 MINUTE WALKING TEST" NEGLI ADOLESCENTI SANI. Balestri, E.; Benedetti, S.; Di Cioccio, G.; Acquaviva, L.; Bertozzi, L. // Scienza Riabilitativa;lug2008, Vol. 10 Issue 3, p22 

    Background The reduction in exercise tolerance is an important issue in patients with cystic fibrosis. It' been amply demonstrated as a program of aerobic reconditioning lead to a greater physical performance and a reduction of dyspnea; The "six-minute walking test" is a tool, held by the...

  • Cystic Fibrosis Pulmonary Guidelines: Airway Clearance Therapies. Flume, Patrick A.; Robinson, Karen A.; Brian P. O'Sullivan; Finder, Jonathan D.; Vender, Robert L.; Willey-Courand, Donna-Beth; White, Terry B.; Marshall, Bruce C. // Respiratory Care;Apr2009, Vol. 54 Issue 4, p522 

    Cystic fibrosis (CF) is a genetic disease characterized by dehydration of airway surface liquid and impaired mucociliary clearance. As a result, there is difficulty clearing pathogens from the lung, and patients experience chronic pulmonary infections and inflammation. Clearance of airway...

  • Airway clearance research in CF: the 'perfect storm' of strong preference and effortful participation in long-term, non-blinded studies. Main, Eleanor // Thorax;Aug2013, Vol. 68 Issue 8, p701 

    The author discusses a study by M. McIlwaine and coworkers conducted to examine patient preference for airway clearance technique in the treatment of cystic fibrosis (CF). Topics include long term randomised controlled trial (RCT), patients preference and dropouts during the trial, and need for...

  • Comparison of Microbiomes from Different Niches of Upper and Lower Airways in Children and Adolescents with Cystic Fibrosis. Boutin, S├ębastien; Graeber, Simon Y.; Weitnauer, Michael; Panitz, Jessica; Stahl, Mirjam; Clausznitzer, Diana; Kaderali, Lars; Einarsson, Gisli; Tunney, Michael M.; Elborn, J. Stuart; Mall, Marcus A.; Dalpke, Alexander H. // PLoS ONE;Jan2015, Vol. 10 Issue 1, p1 

    Changes in the airway microbiome may be important in the pathophysiology of chronic lung disease in patients with cystic fibrosis. However, little is known about the microbiome in early cystic fibrosis lung disease and the relationship between the microbiomes from different niches in the upper...

  • Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells. Stanton, Bruce A.; Coutermarsh, Bonita; Barnaby, Roxanna; Hogan, Deborah // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: P. aeruginosa is an opportunistic pathogen that chronically infects the lungs of 85% of adult patients with Cystic Fibrosis (CF). Previously, we demonstrated that P. aeruginosa reduced wt-CFTR Cl secretion by airway epithelial cells. Recently, a new investigational drug VX-809 has...

  • SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS. Davies, G.; Davies, J. C.; Gill, D. R.; Hyde, S. C.; Boyd, C.; Innes, J. A.; Porteous, D. J.; Cheng, S. H.; Scheule, R. K.; Higgins, T.; Griesenbach, U.; WAlton, E. W. F. // Thorax;Dec2011 Supplement, pA2 

    Introduction and Objectives We undertook a clinical trial of non-viral CFTR gene therapy assessing safety, dose and transgene expression in preparation for a Multi-dose trial (MDT) designed to assess clinical efficacy. Methods A single nebulised and/or nasal dose of plasmid CFTR (pGM169)/GL67A...

  • Bronchoalveolar lavage in children with cystic fibrosis: how many lobes should be sampled? F J Gilchrist // Archives of Disease in Childhood;Mar2011, Vol. 96 Issue 3, p215 

    BACKGROUND: The European Respiratory Society guidance on bronchoalveolar lavage (BAL) in children was published in 2000. It recommended taking one BAL specimen from the most affected lobe or from the right middle lobe in diffuse disease. In 2007, the European Respiratory Society modified the...

  • Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway. Williams, Huw D.; Davies, Jane C. // Thorax;May2012, Vol. 67 Issue 5, p465 

    The article focuses on basic science relation between Pseudomonas aeruginosa and the cystic fibrosis airway. It is stated that infection of P. aeruginosa at early stages can be successfully eradicated from the airway. Host defense and invasion tactics used by the bacteria is also discussed. The...

  • Ceramide in Cystic Fibrosis: A Potential New Target for Therapeutic Intervention. Wojewodka, Gabriella; De Sanctis, Juan B.; Radzioch, Danuta // Journal of Lipids;2011, p1 

    Patients with cystic fibrosis (CF) are afflicted with many symptoms but the greatest challenge is the fight against chronic bacterial infections, leading to decreased lung function and ultimately death. Our group has recently found reduced levels of ceramides in CF patients and mice. Ceramides...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics